Electrophysiological Substrate in Patients with Barlow's Disease

Area of Science:

• Cardiology
• Cardiac Electrophysiology
• Valvular Heart Disease

Background:

• Mitral valve prolapse (MVP) is the most prevalent valvular heart disease, impacting 2-3% of the population.
• Barlow's disease is a specific clinical manifestation of MVP.
• MVP, once considered benign, is now recognized as a risk factor for sudden cardiac death and ventricular arrhythmias.

Purpose of the Study:

• To review current understanding of arrhythmogenesis in MVP.
• To discuss risk stratification for sudden cardiac death in MVP patients.
• To explore treatment options, including advanced catheter ablation techniques.

Main Methods:

• Literature review of arrhythmogenesis in MVP.
• Analysis of risk factors identified through new imaging techniques.
• Evaluation of current and emerging treatment strategies for ventricular arrhythmias in MVP.

Main Results:

• Novel risk factors for arrhythmias in MVP have been identified using advanced imaging.
• Catheter ablation for ventricular arrhythmias in MVP patients presents unique challenges.
• Evidence supports risk stratification and various treatment modalities.

Conclusions:

• MVP is a significant cause of potentially fatal cardiac events.
• Improved diagnostic tools aid in risk assessment.
• Advanced catheter ablation techniques show promise for managing arrhythmias in MVP.